Virtual Medicinal Product (VMP) - Irinotecan pegylated liposomal 43mg/10ml dispersion for infusion vials

Navigation

Name Details

Name Start Date End Date
Name Current Name Irinotecan pegylated liposomal 43mg/10ml dispersion for infusion vials Start Date 01-05-2021 End Date
Previous Name Previous Name Irinotecan pegylated liposomal 43mg/10ml solution for infusion vials Start Date 12-02-2020 End Date 30-04-2021
Abbreviated Name Abbreviated Name Irinotecan pegylated liposomal 43mg/10ml inf vials Start Date 12-02-2020
Previous Abbreviated Name Irinotecan liposomal pegylated 50mg/10ml inf vials Previous Start Date 11-12-2018 Previous End Date 11-02-2020

Unit Dose & Form Information

DF Indicator
Discrete
UDFS Indicator
10.0
UDFS UOM
ml
Unit Dose UOM
vial

Summary

Prescribing Status
Valid as a prescribable product
Controlled Drug Category
No Controlled Drug Status
Route
Intravenous
Form
Dispersion for infusion
Ontology Form/Route
dispersioninfusion.intravenous
Name Basis
rINN - Recommended International Non-proprietary

Codes

ATC Code
L01CE02
BNF Start Date End Date
Current BNF 08010500 Start Date 04-04-2022 End Date
Previous BNF 08010500 Start Date 28-06-2017 End Date 03-04-2022
SNOMED Codes
Code Start Date End Date
34155811000001108 17-02-2017

VMP Ingredients

VMP ingredients table
Name Basis of Strength Description BOSS Strength and UOM (Nmr) Strength and UOM (Dmr)
Irinotecan sucrosofate salt pegylated liposomal Based on Base Substance Irinotecan 4.3 mg 1 ml

Parent Products

Virtual Medicinal Product Pack (VMPP) Information

Pack Size Drug Tariff Price Drug Tariff Payment Category
1 vial